DFTX insider trading — Definium Therapeutics, Inc.
No open-market insider purchases or sales were filed for Definium Therapeutics, Inc. (DFTX) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent DFTX insider transactions
Every Form 4 filed by Definium Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | Karlin Daniel | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 10,853 | $36.57 | $397K | Form 4 |
| Sep 25, 2026 | Barrow Robert | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 31,550 | $36.57 | $1.15M | Form 4 |
| Sep 25, 2026 | Wiley Matthew T. | Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 3,097 | $36.57 | $113K | Form 4 |
| Sep 25, 2026 | Sullivan Mark | Chief Legal Officer | S · Sale · 10b5-1 | Direct | 14,051 | $36.57 | $514K | Form 4 |
| Sep 25, 2026 | Roberts Brandi | Chief Financial Officer | S · Sale · 10b5-1 | Direct | 3,377 | $36.57 | $123K | Form 4 |
| Sep 18, 2026 | Vallone Carol A | Director | M · Option exercise | Direct | 1,086 | $35.52 | $39K | Form 4 |
| Sep 18, 2026 | Krebs Andreas | Director | M · Option exercise | Direct | 1,629 | $35.52 | $58K | Form 4 |
| Sep 14, 2026 | Sullivan Mark | Chief Legal Officer | A · Grant/award | Direct | 125,000 | — | — | Form 4 |
| Sep 14, 2026 | Roberts Brandi | Chief Financial Officer | A · Grant/award | Direct | 125,000 | — | — | Form 4 |
| Sep 14, 2026 | Wiley Matthew T. | Chief Commercial Officer | A · Grant/award | Direct | 125,000 | — | — | Form 4 |
| Sep 14, 2026 | Karlin Daniel | Chief Medical Officer | A · Grant/award | Direct | 200,000 | — | — | Form 4 |
| Sep 14, 2026 | Barrow Robert | Chief Executive Officer | A · Grant/award | Direct | 750,000 | — | — | Form 4 |
| Sep 3, 2026 | Barrow Robert | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 19,023 | $37.94 | $722K | Form 4 |
| Sep 2, 2026 | Barrow Robert | Chief Executive Officer | A · Grant/award · 10b5-1 | Direct | 40,000 | — | — | Form 4 |
| Aug 12, 2026 | Sullivan Mark | Chief Legal Officer | A · Grant/award | Direct | 62,500 | — | — | Form 4 |
| Aug 12, 2026 | Roberts Brandi | Chief Financial Officer | A · Grant/award | Direct | 62,500 | — | — | Form 4 |
| Aug 12, 2026 | Wiley Matthew T. | Chief Commercial Officer | A · Grant/award | Direct | 62,500 | — | — | Form 4 |
| Aug 12, 2026 | Barrow Robert | Chief Executive Officer | A · Grant/award | Direct | 375,000 | — | — | Form 4 |
| Aug 12, 2026 | Karlin Daniel | Chief Medical Officer | A · Grant/award | Direct | 100,000 | — | — | Form 4 |
DFTX insider trading FAQ
Are insiders buying DFTX stock?
Not on the open market. In the last 90 days, Definium Therapeutics, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading DFTX?
No insider bought or sold on the open market in the last 90 days.
Where does DFTX insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.